The Green Rush

This summer, we are revisiting our extensive archives, curating a selection from over 300 past episodes. This collection will feature memorable moments, insightful interviews, and some of the team’s favorite episodes, providing new listeners and long-time fans an opportunity to explore or rediscover the best of  Green Rush. Stay tuned for the upcoming launch of our new podcast in the fall, “Alternatively Speaking.”

This week, we’re bringing back our conversation with Emmy-winning Writer, Producer, and Director Donick Cary. Well known in the television and film industry for his work on shows like The David Letterman Show, The Simpsons, Silicon Valley, and Parks and Recreation, Donick is also the writer and director of the Netflix hit, Have a Good Trip. This documentary mixes comedy with a thorough investigation of psychedelics, exploring the pros, cons, science, history, future, pop cultural impact, and cosmic possibilities of hallucinogens. It also includes some of the best psychedelic trip stories from celebrities like Sting, Sarah Silverman, Ben Stiller, A$AP Rocky, and the late greats Carrie Fisher and Anthony Bourdain.

Our host Lewis sat down with Donick to discuss his film in greater depth, including what drew his attention to psychedelics, his inspiration for developing a documentary around stories of psychedelic trips (and how he sold that idea to Netflix), his own introduction to psychedelics, and whether he’s turned to psychedelics to help deal with the anxiety caused by the COVID-19 pandemic.

Donick is one of the most talented writers in Hollywood, and it was a real treat to have him join us to discuss his journey. So don’t sit back, lean forward, and enjoy!

About Filmmaker and Writer Donick Cary: Emmy-winning Writer, Producer, and Director Donick Cary got his start writing for Late Night with David Letterman. He continued writing for Dave at The Academy Awards (but not the Oprah-Uma joke) and served as both Head Writer and “The Guy in the Bear Suit” on Late Show with David Letterman. After five years in late night, Cary moved to The Simpsons, where he served as a Co-Executive Producer for seasons seven through eleven, winning an Emmy and penning many memorable episodes including “D’oh-in in The Wind,” “In Marge We Trust” (Mr. Sparkle), and “Hell Toupee” (Homer gets the hair transplants of a killer).

Social Media:

Other Links/Mentions:

Show Credits:

Special thanks to our Program Director, Shea Gunther.

You can learn more about how KCSA can help your cannabis and psychedelic companies by visiting www.kcsa.com or emailing [email protected]. You can also connect with us via our social channels:

X: @KCSAPodcastLabs

Overview:

NewLake Capital Partners (OTCQX: NLCP) is an internally managed real estate investment trust (REIT) that has invested and committed about $445 million in capital to state-licensed cannabis operators across 12 states. As co-founder of NewLake, Jarrett spearheads portfolio management, capital raising, and overall operations for the company’s 32 properties spanning 1.7 million square feet.

NewLake Links and Socials:

—

Show Credits:

You can learn more about how KCSA can help your cannabis and psychedelic companies by visiting www.kcsa.com or emailing [email protected]. You can also connect with us via our social channels:

— 

Show Notes:

Key Takeaways:

—

Welcome to the Green Rush, a KCSA Strategic Communications Production, a weekly conversation at the intersection of cannabis, psychedelics, the capital markets, and culture.

This week, Anne Donohoe sat down with James Krouse, CEO of Flower Power Genetics, to talk about how his company is working to preserve and reintroduce the best purebred medicinal cannabis strains into the marketplace. James walked our host through his past 30 years of work including how he has painstakingly researched, collected and preserved original Nevil medical seeds, dating back to the golden age of cannabis in the late 1980s and 1990s. James also touches on the medicinal benefits of these original strains, feedback he’s received from the industry and how rescheduling will allow for more research opportunities for his group. 

If you are interested in learning more about James or Flower Power, you can follow them across social channels and visit the links found in our show notes. 

So, sit back and enjoy our conversation with James Krouse, CEO of Flower Power Genetics. 

Links, mentions, and socials:

Show Credits:

This episode was hosted by Anne Donohoe of KCSA Strategic Communications. 

Special thanks to our Program Director, Shea Gunther.

You can learn more about how KCSA can help your cannabis and psychedelic companies by visiting www.kcsa.com or emailing [email protected]. You can also connect with us via our social channels:

X: @The_GreenRush

Instagram: @thegreenrush_podcast

LinkedIn: linkedin.com/company/thegreenrushpodcast

Facebook: facebook.com/TheGreenRushPodcast 

YouTube: youtube.com/channel/UCuEQkvdjpUnPyhF59wxseqw?disable_polymer=true

Welcome to the Green Rush, a KCSA Strategic Communications Production, a weekly conversation at the intersection of cannabis, psychedelics, the capital markets, and culture.

This week, Anne Donohoe sat down with Gibran Washington, CEO of ETHOS Cannabis, a medical forward multi-state operator with operations in Pennsylvania, Massachusetts and Ohio.   In today’s conversation, Gibran opens up to Anne about his journey from corporate America to cannabis and how life lessons learned at a young age from his mother and father shaped his leadership style. Gibran also shares details about ETHOS’ unique relationship with Thomas Jefferson University to study cannabis’ effect on various conditions including anxiety, insomnia and depression; his thoughts on the potential benefits of rescheduling; and how ETHOS is preparing for the opening up of Ohio’s adult use marketplace.  

If you are interested in learning more about Gibran or ETHOS Cannabis, visit the links in our show notes. Also, be sure to follow Gibran and ETHOS across all social platforms.

So, sit back and enjoy our conversation with Gibran Washington of ETHOS Cannabis. 

Links, mentions, and socials:

Show Credits:

This episode was hosted by Anne Donohoe of KCSA Strategic Communications. 

Special thanks to our Program Director, Shea Gunther.

You can learn more about how KCSA can help your cannabis and psychedelic companies by visiting www.kcsa.com or emailing [email protected]. You can also connect with us via our social channels:

X: @The_GreenRush

Instagram: @thegreenrush_podcast

LinkedIn: linkedin.com/company/thegreenrushpodcast

Facebook: facebook.com/TheGreenRushPodcast 

YouTube: youtube.com/channel/UCuEQkvdjpUnPyhF59wxseqw?disable_polymer=true

Welcome to the Green Rush, a KCSA Strategic Communications Production, a weekly conversation at the intersection of cannabis, psychedelics, the capital markets and culture.

This week Anne Donohoe sits down with Tim Pickett, CEO of KindlyMD, a patient-first healthcare and healthcare data company uniquely integrating traditional primary care with medicinal cannabis. In our conversation, Anne and Tim explore his professional evolution from being a board-certified physician assistant to founding a medical cannabis business in one of the most conservative states in the union in Utah.  

Anne and Tim touch on a number of topics including KindlyMD’s IPO on the Nasdaq, DEA rescheduling and the company’s unique position as the only service provider of its kind that has Medicare, Medicaid and Commercial insurance payer contracts. Tim also gives our listeners insight into the machinations of the Utah cannabis marketplace, how it structurally differs from its neighboring states and how rescheduling or descheduling would potentially impact the market. 

If you are interested in learning more about Tim or KindlyMD, visit the links in our show notes. Also, be sure to follow Tim and KindlyMD, across all social platforms.

So, sit back and enjoy our conversation with Tim Pickett, CEO of KindlyMD. 

Links, mentions, and socials:

Show Credits:

This episode was hosted by Anne Donohoe of KCSA Strategic Communications. 

Special thanks to our Program Director Shea Gunther.

You can learn more about how KCSA can help your cannabis and psychedelic companies by visiting www.kcsa.com or emailing [email protected]. You can also connect with us via our social channels:

X: @The_GreenRush

Instagram: @thegreenrush_podcast

LinkedIn: linkedin.com/company/thegreenrushpodcast

Facebook: facebook.com/TheGreenRushPodcast 

YouTube: youtube.com/channel/UCuEQkvdjpUnPyhF59wxseqw?disable_polymer=true

Welcome to the Green Rush, a KCSA Strategic Communications Production, a weekly conversation at the intersection of cannabis, psychedelics, the capital markets and culture.

This week Anne Donohoe and Kris Krane are back to sit down with Paul Armentano, Deputy Director of NORML. Paul joined our hosts this week to talk about his career of advocacy work within the cannabis space and to highlight the positives and shortcomings with the DEA’s proposed move to reschedule cannabis. Paul walked us through his thoughts, which can also be found in his recent op-ed in the Orange County Register, as well as what he thinks will move the needle through the DEA open comment period. 

Kris and Paul also dive into the debate of incrementalism vs full reform for cannabis as well as why it’s critical to ensure advocacy organizations like NORML stay funded and operational, even as the U.S. becomes more accepting of cannabis.  

If you are interested in learning more about Paul or how to get more involved in NORML’s work, visit the links in our show notes. Also, be sure to follow NORML, as well as the organization’s local chapters, across all social platforms.

So, sit back and enjoy our conversation with Paul Armentano of NORML.

Links, mentions, and socials:

Show Credits:

This episode was hosted by Anne Donohoe and Kris Krane of KCSA Strategic Communications. 

Special thanks to our Program Director Shea Gunther.

You can learn more about how KCSA can help your cannabis and psychedelic companies by visiting www.kcsa.com or emailing [email protected]. You can also connect with us via our social channels:

X: @The_GreenRush

Instagram: @thegreenrush_podcast

LinkedIn: linkedin.com/company/thegreenrushpodcast

Facebook: facebook.com/TheGreenRushPodcast 

YouTube: youtube.com/channel/UCuEQkvdjpUnPyhF59wxseqw?disable_polymer=true

Welcome to the Green Rush, a KCSA Strategic Communications Production, a weekly conversation at the intersection of cannabis, psychedelics, the capital markets and culture.

This week we wanted to revisit our conversation with special guest Dr. Hans Eriksson, Chief Medical Officer for HMNC Brain Health. Hans joined us to discuss his role at HMNC, the company’s research and development efforts to identify and bring to market treatments for mental health disorders, and the latest news and progress on the psychedelics movement.

With the death of the beloved actor Matthew Perry back in the news, we spoke with Hans about illicit ketamine use and how the news about Perry’s use was presented by the media, and the risks associated with the treatment.

If you are interested in learning more about Hans or to check out the latest updates from HMNC Brain Health, visit the links in our show notes. Also, be sure to follow HMNC and Hans on LinkedIn.

So, sit back and enjoy our conversation with Dr. Hans Eriksson of HMNC Brain Health.

Links, mentions, and socials:

Show Credits:

This episode was hosted by Nick Opich and Anne Donohoe of KCSA Strategic Communications. 

Special thanks to our Program Director Shea Gunther.

You can learn more about how KCSA can help your cannabis and psychedelic companies by visiting www.kcsa.com or emailing [email protected]. You can also connect with us via our social channels:

X: @KCSAPodcastLabs

Instagram: @KCSAPodcastLabs

LinkedIn: linkedin.com/company/thegreenrushpodcast

Welcome to the Green Rush, a KCSA Strategic Communications Production, a weekly conversation at the intersection of cannabis, psychedelics, the capital markets, and culture.

This week’s episode is a crossover roundtable event with our friends at the Multidisciplinary Association for Psychedelic Studies (MAPS) covering the DEA’s proposed rescheduling of cannabis from Schedule I to a Schedule III drug. Hosted by our very own Anne Donohoe, the Q&A discussion also features Betty Aldworth, Director of Communications & Post-Prohibition Strategy at MAPS, Karen O’Keefe, Director of State Policies at Marijuana Policy Project (MPP) and Paul Armentano, Deputy Director at NORML. 

With the unprecedented federal drug policy change on the near horizon, MAPS assembled leaders with more than 50 years of combined experience in the cannabis policy reform movement to talk about what these changes are, why they matter, what myths need debunking, and what still needs to be done. Some of the topics covered in this conversation include the impact rescheduling will have on research and development of cannabis-based medicines, criminal law and systems-impacted people, cannabis banking and interstate commerce and veteran affairs. 

If you are interested in learning more about how MAPS, MPP or NORML have played pivotal roles in implementing drug policy reform over the decades, be sure to follow them all on their socials linked in our show notes and visit their websites to follow their advocacy work.  

So, sit back and enjoy this crossover Q&A discussion on the future of cannabis drug policy. 

Links and mentions in the show

Links to the guest’s company and social media accounts

Show Credits:

This episode was hosted by Anne Donohoe of KCSA Strategic Communications.

Special thanks to our Program Director, Shea Gunther and to the MAPS team. 

You can learn more about how KCSA can help your cannabis and psychedelic companies by visiting www.kcsa.com or emailing [email protected]. You can also connect with us via our social channels:

X: @KCSAPodcastLabs

Instagram: @KCSAPodcastLabs

LinkedIn: linkedin.com/company/thegreenrushpodcast

Welcome to the Green Rush, a KCSA Strategic Communications Production, a weekly conversation at the intersection of cannabis, psychedelics, the capital markets, and culture. 

This week Lewis Goldberg and Kris Krane sit down with long-time friend of the podcast Adam Smith, Founder and President of the Alliance for Sensible Markets, to talk about the DEA’s historic decision to reclassify cannabis from a Schedule I to Schedule III drug. As a long-time advocate working behind the scenes for decades to reverse the US’s draconian cannabis laws, Adam is cautiously optimistic about this development, noting that one of the most exciting changes will be the increase in research opportunities of cannabis for medical use.

Adam and our hosts also discuss the potential impacts this development will have on the industry and markets, the elimination of the 280E tax, and the potential global rescheduling of cannabis under the UN Single Convention on Narcotics. As the industry awaits what comes next, the team identifies M&A opportunities and clarity on interstate commerce as key areas of interest to watch over the coming months. 

If you are interested in learning more about Adam and how his organization is fighting for a more sustainable legal cannabis industry, visit the links in our show notes and be sure to follow Adam and the Alliance for Sensible Markets on LinkedIn.

So, sit back and enjoy our conversation with Adam Smith, Founder of Alliance for Sensible Markets. 

Links and mentions in the show

Links to the guest’s company and social media accounts

Show Credits:

This episode was hosted by Lewis Goldberg and Kris Krane of KCSA Strategic Communications.

Special thanks to our Program Director, Shea Gunther.

You can learn more about how KCSA can help your cannabis and psychedelic companies by visiting www.kcsa.com or emailing [email protected]. You can also connect with us via our social channels:

X: @KCSAPodcastLabs

Instagram: @KCSAPodcastLabs

LinkedIn: linkedin.com/company/thegreenrushpodcast

Welcome to the Green Rush, a KCSA Strategic Communications Production, a weekly conversation at the intersection of cannabis, psychedelics, the capital markets, and culture. 

This week hosts Anne and Phil speak with Ian Dominguez, founder and CIO of Delta Emerald Ventures, a leader in intelligent cannabis investing and industry insight. Ian joins Anne and Phil to talk about the booming market in hemp-derived products, including the growing drinks category, industry consolidation, and the conditions that lead him to start up CannaDataCon, a conference focusing on the intersection of legal cannabis and good data strategy.

Links, mentions, and socials:

To learn more about CannaDataCon, check out Ian’s welcome remarks. And to go deeper into hemp beverages, check out Delta Emerald’s view on the category and hear how leading brands describe the regulatory environment.

Show Credits:

This episode was hosted by Phil Carlson and Anne Donohoe of KCSA Strategic Communications.

Special thanks to our Program Director Shea Gunther.

You can learn more about how KCSA can help your cannabis and psychedelic companies by visiting www.kcsa.com or emailing [email protected]. You can also connect with us via our social channels:

Twitter: @KCSAPodcastLabs

Instagram: @KCSAPodcastLabs

LinkedIn: linkedin.com/company/thegreenrushpodcast